Victor Moyo
Directeur Technique/Scientifique/R&D chez TRAWS PHARMA, INC.
Profil
Victor Moyo is currently the Chief Medical Officer at Traws Pharma, Inc. since 2023 and at OncoPep, Inc. since 2022.
He holds a doctorate degree from the University of Zimbabwe.
Postes actifs de Victor Moyo
| Sociétés | Poste | Début |
|---|---|---|
| TRAWS PHARMA, INC. | Directeur Technique/Scientifique/R&D | 24/10/2023 |
OncoPep, Inc.
 OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | Corporate Officer/Principal | 01/05/2022 |
Formation de Victor Moyo
| University of Zimbabwe | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TRAWS PHARMA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | Finance |
